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ABSTRACT
Health benefits packages (HBPs) are increasingly used 
in many countries to guide spending priorities on the 
path towards universal health coverage. Their design is, 
however, informed by an uncertain evidence base but 
research funds available to address this are limited. This 
gives rise to the question of which piece of research 
relating to the cost- effectiveness of interventions would 
most contribute to improving resource allocation. We 
propose to incorporate research prioritisation as an 
integral part of HBP design. We have, therefore, developed 
a framework and a freely available companion stand- 
alone tool, to quantify in terms of net disability- adjusted 
life- years (DALYs) averted, the value of research for the 
interventions considered for inclusion in a package. 
Using the tool, the framework can be implemented using 
sensitivity analysis results typically reported in cost- 
effectiveness studies. To illustrate the framework, we 
applied the tool to the evidence base that informed the 
Malawi Health Sector Strategic Plan 2017–2022. Out 
of 21 interventions considered, 8 investment decisions 
were found to be uncertain and three showed strong 
potential for research to generate large health gains: 
‘male circumcision’, ‘community- management of acute 
malnutrition in children’ and ‘isoniazid preventive therapy 
in HIV +individuals’, with a potential to avert up to 65 
762, 36 438 and 20 132 net DALYs, respectively. Our work 
can help set research priorities in resource- constrained 
settings so that research funds are invested where they 
have the largest potential to impact on the population 
health generated via HBPs.
INTRODUCTION
To achieve Universal Health Coverage of 
their populations1 using a limited resource 
envelope, governments of low- and middle- 
income countries (LMIC) inevitably must 
make hard choices when selecting the health-
care interventions that their population has 
access to, free- of- charge, through publicly 
pooled funds.
Recent advances in methods to identify 
the set of interventions to be provided, that 
constitute what is known as a Health Bene-
fits Package (HBP), recommend explicit 
consideration of the population net health 
effect (pNHE) associated with including 
in the package each intervention under 
Summary box
 ► Evidence on the costs and benefits of healthcare in-
terventions considered for inclusion in a health ben-
efits package (HBP) is inevitably uncertain.
 ► Methods such as value of information analysis can 
be used to guide research priorities, but their ap-
plication requires detailed knowledge of statistical 
theory and the availability of data that are often not 
reported in the published cost- effectiveness studies 
that form the evidence base for HBP design. As a re-
sult, there is currently no framework in place to help 
align research strategies with the evidential needs 
of HBPs.
 ► We provide a framework with an easy- to- use ac-
companying Value of Information for Health Benefits 
Package design (VOI- HBP) tool to estimate the 
health benefits of undertaking research to inform 
the inclusion and exclusion of interventions within 
HBPs. These can be used to prioritise the alloca-
tion of research funds. The tool only requires data 
that are generally available from published cost- 
effectiveness studies.
 ► Application of the framework and VOI- HBP tool to 
the evidence base that informed the Malawi Health 
Sector Strategic Plan for 2017–2022 identified 
three interventions to consider when establishing 
healthcare research priorities: ‘male circumcision’, 
‘community- management of acute malnutrition 
in children’ and ‘isoniazid preventive therapy in 
HIV +individuals’.
 ► Our work provides a practical approach that can be 
used alongside HBP design to guide the allocation of 
research funds to where these can have the largest 
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consideration.2 3 This metric accounts for both the health 
expected to be generated by the intervention, and the 
losses in health associated with funding the interven-
tion rather than addressing other healthcare priorities. 
The assessment of the pNHE of relevant interventions 
is informed by data coming from a range of sources. 
National surveys and bottleneck analyses are often used 
to assess population needs and interventions’ capacity 
to cover them, whereas estimates of per patient cost 
and health benefit typically come from published cost- 
effectiveness analyses.
Cost and health benefit estimates are, however, uncer-
tain, due to limited data availability on key quantities 
such as drug and programme costs, clinical effectiveness 
and its long- term implications for patients’ quality of life 
and life expectancy.3 4 Approaches to quantifying uncer-
tainty in the cost- effectiveness of interventions consid-
ered for inclusion in HBPs have been proposed and used, 
such as stochastic league tables whereby interventions 
are ranked by their probability of being cost- effective.5 
These approaches, however, fall short of guiding policy 
makers as to how they should respond to uncertainty, 
that is whether this uncertainty matters to the resource 
allocation process and should be addressed by funding 
further research. As a result, research strategies may not 
be aligned with the evidential needs of HBPs. We, there-
fore, propose a framework to support the concomitant 
design of HBPs and research prioritisation, based on an 
assessment of where additional evidence would be most 
valuable in generating health gains.
Our framework builds on value of information (VOI) 
methods6 to quantify the pNHE of reducing uncertainty 
through further research. The contribution of our work is 
to tailor the application of VOI methods to the evidence 
base that typically informs HBPs, namely secondary cost- 
effectiveness data.
VOI methods or other methods similarly grounded in 
statistical decision theory, are often used to determine 
how much one may lose out by taking a decision with 
uncertain outcomes and therefore how much benefit 
there is to reducing uncertainty via research.6 7 Their 
application usually requires estimates of uncertainty 
around outcomes, or around the quantities that drive 
them, to produce probabilistic simulations of the values 
that outcomes could take.8 9 This data is, however, not 
readily available from published cost- effectiveness 
studies that overwhelmingly constitute the evidence base 
informing HBPs. The high burden of information inputs 
and technical knowledge associated with the application 
of statistical decision theory methods have impeded the 
use of VOI methods for aligning research funds alloca-
tion with evidential requirements.
We have, therefore, developed a freely available tool—
the Value of Information for Health Benefits Package 
design (VOI- HBP) tool—that addresses these two hurdles 
and estimates the value of research using only the informa-
tion that is typically reported in cost- effectiveness studies 
and without the need for undertaking supplementary 
statistical analysis. Our framework and companion VOI- 
HBP tool aim to provide a practical approach to informing 
deliberations about research priorities in LMIC countries 
so that the limited resources allocated to HBPs achieve 
greater gains in population health.
We apply the VOI- HBP tool to the evidence base that 
informed the HBP of Malawi’s Health Sector Strategic 
Plan (HSSP) 2017–202210. Malawi has used a HBP since 
the early 2000s to prioritise interventions for funding 
within its national health budget. In addition, clear ambi-
tions have been set to secure funds for health research, 
with the government agreeing to commit 2% of its 
overall health budget to research activities and overseas 
development partners being required to commit 5% 
of their assistance funds.11 12 Malawi’s National Health 
Research agenda12 is developed through structured 
deliberations of a large panel of experts and stakeholders 
from the Ministry of Health, academic institutions, 
service providers and bilateral and multilateral donors. 
Alongside several criteria such as equity impacts and 
public acceptability of research, these deliberations are 
informed by qualitative assessments of evidence needs, 
where particular attention is given to evidence gaps on 
efficacy. Whether these identified evidence gaps translate 
to uncertainty in cost- effectiveness and could challenge 
the current allocation of limited resources is, however, 
not considered. In this context, the Ministry of Health13 
acknowledges the need to strengthen these deliberations 
with quantitative estimates of where research could make 
the largest contributions to population health.
A FRAMEWORK TO PRIORITISE RESEARCH: QUANTIFYING THE 
HEALTH BENEFITS FROM BETTER EVIDENCE
Core principles
The central tenet of the framework is that, by resolving 
uncertainty around which healthcare interventions 
would be expected to improve net population health if 
invested in, and which would not, research can improve 
HBP design and thereby generate additional population 
health gains. This section describes the principles under-
pinning the quantification of these gains (or losses), 
summarised as pNHE and shows how this can guide 
research prioritisation.
The decision to include an intervention in a HBP can 
be informed by an assessment of its expected pNHE, 
which encompasses the total health generated, net of 
the health opportunity costs imposed by funding it, 
and is often expressed in net disability- adjusted life- 
years (DALYs) averted.3 Interventions that are expected 
to generate a positive pNHE, that is to provide more 
health than would have been generated if the resources 
invested had instead been used to fund other interven-
tions, would thus be potentially included in the package. 
These interventions are described as being cost- effective. 
Conversely, interventions that are expected to generate a 
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opportunity costs compared with the health gains they 
offer, are not cost- effective.
However, there is typically uncertainty about the 
magnitude of pNHE expected to be achieved by each 
intervention as the set of clinical, epidemiological and 
economic quantities that underpin this calculation (eg, 
treatment effect size, baseline survival rate and quality 
of life, prevalence of disease, cost of care) are uncertain 
themselves. This level of uncertainty can be described 
by a probability distribution that shows the likelihood 
that the pNHE estimate could take a range of values, as 
is illustrated in figure 1. Linking together each possible 
value the pNHE estimate could take and the likelihood 
of each value, we can derive a ‘best guess’ of how much 
population net health an intervention would be expected 
to generate. In figure 1, the ‘best guess’ of pNHE is nega-
tive for intervention A (ie, intervention A is not expected 
to be cost- effective) and positive for intervention B (ie, 
intervention B is expected to be cost- effective). For both 
interventions we are unsure whether the ‘best guess’, 
formulated based on currently available evidence, will 
be the true outcome. For intervention A, however, a net 
health loss is expected even in the current most optimistic 
scenario. In other words, despite substantial uncertainty 
around future outcomes, it is fairly certain intervention 
A will not be cost- effective. On the contrary, for interven-
tion B, the range of plausible pNHE values spans from 
net health losses to net health gains, indicating uncer-
tainty in whether, on the basis of pNHEs, the intervention 
should be excluded or included from the package.
If currently available evidence can support two courses 
of action, there is a risk of taking the wrong decision. A 
second step is therefore required to assess whether this 
risk is tolerable or should be reduced. Such an assess-
ment can be undertaken by applying VOI methods6 
and involves the quantification of the consequences of 
taking the wrong decision. For intervention B, which 
is currently expected to be cost- effective, these conse-
quences correspond to the net health losses incurred by 
incorrectly including this intervention in the package; 
they are represented by the shaded part of the pNHE 
distribution.
By combining an assessment of the potential negative 
effects on population net health of making an incorrect 
investment decision with an assessment of their like-
lihood, it is possible to estimate how much population 
net health research could generate. If, for instance, addi-
tional evidence was to suggest that implementing inter-
vention B would most likely generate a net health loss, 
it would not be included, and a net health loss would 
thereby be avoided. Conversely, if an intervention was 
originally expected to be cost- ineffective but was subject 
to further research and found to offer net health gains, 
the research and subsequent updating of the HBP could 
allow access to a cost- effective intervention.
The greater the magnitude and likelihood of the 
potential net health losses associated with taking a deci-
sion informed by imperfect evidence, the more pNHE 
research can generate. The pNHE of research is indeed 
expected to be much larger for intervention B, for which 
potential net health losses from incorrectly including it 
in the HBP are substantial and quite likely, than for inter-
vention A, for which the likelihood of forgoing any net 
health gain by excluding it is near zero. By undertaking 
this assessment for each of the interventions considered 
for inclusion in the package, it is possible to identify 
which interventions research would be most valuable for.
Generic data requirements
The pNHE metric can be derived from population- level 
estimates of the incremental costs and incremental health 
benefits of implementing the intervention compared 
with the status- quo, combined with three quantities: (1) 
the period over which interventions are expected to be 
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delivered once included in a package; (2) the discount 
rate used to adjust the values of costs and benefits occur-
ring in the future and (3) the health opportunity cost 
of spending limited healthcare funds that represents the 
rate at which incremental costs are converted into health 
forgone elsewhere in the healthcare system. To quantify 
the uncertainty around the pNHE to be generated by 
each intervention, these three decision- analytic parame-
ters need to be linked with probability distributions (as 
opposed to point estimates) of the incremental costs and 
incremental health benefits scaled to the population 
groups that stand to receive each intervention.
THE VOI-HBP TOOL TO SUPPORT APPLICATION OF THE 
FRAMEWORK
Since probability distributions of incremental costs and 
incremental health benefits are usually not available 
from published cost- effectiveness studies, the uncertainty 
around each intervention’s expected pNHE and an esti-
mate of the health benefits from improved evidence 
cannot be easily quantified. We, therefore, developed the 
VOI- HBP tool to bridge this data gap and perform VOI 
analysis to quantify the pNHE that a better- evidenced 
HBP could generate. The tool exploits sensitivity anal-
ysis results reported in the cost- effectiveness literature 
to produce probability distributions of incremental 
costs and incremental health benefits, based on which 
it derives a probability distribution of pNHE and, using 
VOI analysis, generates estimates of the pNHE from 
research expressed in DALYs. The VOI- HBP tool and a 
guide for use are available at: https://www. york. ac. uk/ 
che/ research/ global- health/ methods- guidelines/# tab- 
5.
A summary of the VOI- HBP tool’s input data require-
ments and output is provided in figure 2. Three sets of 
input are to be collated into a single Excel worksheet to 
be uploaded to the VOI- HBP tool. The first set consists 
of the three decision- analytic parameters listed in the 
generic data requirements section that are common to 
all interventions (analytic time- horizon, discount rate(s) 
and health opportunity cost estimate). The second set 
consists of ‘best guesses’ point estimates of incremental 
health benefits, incremental costs and target population 
for each intervention. The third set consists of sensitivity 
analysis results reported in cost- effectiveness studies. To 
ensure wide usability, the tool only requires input that 
can be relatively easily read off from graphs, plots or 
tables (see user- guide for more details).
Sensitivity analysis results of cost- effectiveness studies 
may be reported using a wide range of metrics and 
media beyond conventional confidence intervals or stan-
dard errors. For instance, univariate sensitivity analysis 
results, where changes in incremental cost and benefit 
are observed in response to changes in selected key input 
quantities evaluated one at a time, are typically reported 
by tornado plots. In contrast, probabilistic sensitivity anal-
ysis results, where probability distributions are fitted to 
each input parameters that are varied simultaneously and 
randomly sampled, can be reported via: (1) scatterplots 
of the resulting simulations of incremental costs against 
incremental benefits; (2) histograms of incremental cost 
effectiveness ratios or (3) cost- effectiveness probabilities 
for different willingness- to- pay values for a DALY averted 
(or other summary metric of health outcomes). Using a 
range of assumptions and statistical methods tailored to 
the type of metrics and medium used for reporting sensi-
tivity analysis results, the VOI- HBP tool extracts for each 
intervention information on estimates of correlation and 
variance of incremental costs and incremental health 
benefits to fit probability distributions and perform a 
probabilistic simulation of costs and benefits. It then 
expresses simulated costs as health losses based on the 
health opportunity cost estimate of spending limited 
healthcare funds and combines them with simulated 
health benefits to generate a probability distribution of 
net health effect. The latter is then scaled to the target 
population that is to benefit from the intervention, over 
the time- horizon that it is expected to remain in place.
For those interventions without any sensitivity anal-
ysis data, the tool provides an exploratory analysis of 
the potential value of research. It simulates a probability 
distribution of pNHE using variances and correlation 
estimates that are equal to the average of the values 
extracted for the set of interventions for which a sensi-
tivity analysis output was available. A summary of the 
VOI- HBP tool’s statistical methods and assumptions is 
described in figure 2 and the complete description is 
provided in the user- guide.
AN APPLICATION TO MALAWI’S HBP
Data inputs
For 67 interventions considered in the HBP of Malawi’s 
HSSP (2017–2022), ‘best guess’ point estimates of (1) 
incremental costs and incremental health benefits (in 
DALYs) against a ‘do- nothing’ alternative and (2) popu-
lation subgroups that stand to benefit from interventions 
(taking into account barriers to access and care demand) 
Figure 2 Tool's input data requirements and statistical 
methods and assumptions underpinning the computation of 
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were available.3 Costs and benefits point estimates came 
from studies of the Tuft Global Health Cost- Effectiveness 
registry and WHO’s CHOosing Interventions that are 
Cost- effective dataset whereas target population sizes for 
each intervention and their realistic levels of coverage 
came from the Clinton Health Access Initiative.
Of those 67 interventions, the costs and benefits of 21 
interventions were informed by cost- effectiveness studies 
that reported sensitivity analyses results. We applied our 
framework to this subset of 21 interventions. The type 
of sensitivity analysis results reported is described in 
table 1 and the nature of the information extracted and 
collated into the tool’s input data file is described in the 
user- guide.
Interventions were assumed to remain in place for 20 
years and costs and health benefits were discounted at 
3% per annum.14 In line with previous work on Malawi 
HBP,3 we used a measure of health opportunity cost of 
US$61/averted DALY that is, for every US$61 spent on 
an intervention, one averted DALY would be displaced 
elsewhere in the healthcare system.
What drives uncertainty in whether to include an intervention 
in the HBP?
Figures 3 and 4 rank the 21 interventions by expected 
population incremental health benefit and pNHE 
respectively, discounted over the 20- year time horizon, 
where error bars indicate uncertainty. Comparison of the 
two rankings underlines the importance of informing 
investment decisions by considering the health oppor-
tunity costs imposed by funding interventions alongside 
expected incremental health benefits, as opposed to 
solely focusing on the latter. For instance, while figure 3 
shows that the population incremental health benefit of 
‘paediatric antiretroviral therapy (ART)’ (intervention 
(int.) 42) is expected to be sizeable, figure 4 indicates 
that these benefits would not offset the health displaced 
elsewhere in the Malawi healthcare system by funding this 
intervention which, overall, would imply a net burden 
of 6.5 million additional DALYs. Overall, among the 21 
interventions considered, 13 are expected to generate a 
positive pNHE, that is, to be cost- effective, with the top 
Table 1 Type of analyses undertaken and medium used to report results in the subset of 21 interventions for which a 
sensitivity analysis around cost- effectiveness results had been undertaken
Type of sensitivity 
analysis Medium used to report results
Numbers of 
interventions
Univariate Table of incremental costs and benefits under single parameter changes 5
Tornado plot of ICERs under single parameter changes 2
Probabilistic Raw simulations 2
Scatterplot of incremental costs vs incremental benefits 1
Histogram of ICER 1
Cumulative distribution of ICER 1
Confidence intervals around mean incremental costs and benefits 8
SEs around mean incremental costs and benefits 1
ICER, incremental cost effectiveness ratio
Figure 3 Uncertainty around the expected population incremental health benefits from implementation. DALY, disability- 
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‘best buys’ including ‘male circumcision’ (int. 33 with 
2.6 million net DALYs averted), and ‘first- line manage-
ment of new cases of tuberculosis (TB)’ in adults and in 
children (int. 17 and int. 18 expected to avert a combined 
2 million net DALYs).
Comparison of figures 3 and 4 also indicates that uncer-
tainty around effectiveness may be a poor indicator of 
uncertainty around the investment decision and thus, of 
the need for further research. For instance, while errors 
bars indicate substantial uncertainty around the magni-
tude of incremental health benefits from providing first- 
line treatment to new tuberculosis cases (int. 17 and int. 
18), lower- bound estimates of pNHE suggest that, even 
in a pessimistic scenario, this would avert a minimum of 
1.1 million net DALYs across adults and children. There 
is therefore little uncertainty around the decision to 
include these interventions in the package.
A wide range of pNHE does not, however, neces-
sarily equate with high decision uncertainty. Decision 
uncertainty arises if the range of pNHE spans across 
net health losses to net health gains and thereby could 
support both inclusion and exclusion of the intervention 
in the package. This is the case for eight interventions 
(int. 33, 36, 26, 27, 30, 47, 31, 41) where the error bars 
around expected pNHE cross the x- axis of no effect in 
figure 4. This is particularly apparent for three inter-
ventions: ‘male circumcision’ (int. 33), ‘community- 
management of acute malnutrition in children (CMAM)’ 
(int 36), and ‘isoniazid preventive therapy in HIV +indi-
viduals no TB’ (int. 31). While the first two are expected 
to be cost- effective (expected pNHE >0), the latter is 
expected to be cost- ineffective (expected pNHE <0).
Where is research to support HBP design most valuable?
Once the interventions for which there is uncertainty 
around the investment decision have been identified, 
the crucial step is to evaluate whether this uncertainty is 
consequential to HBP design and thus, worth reducing. 
Figure 4 Uncertainty around the expected population net health effects from implementation. DALYs, disability- adjusted 
life- years; MDR, Multidrug resistant; TB, Tuberculosis; ART, Antiretroviral therapy; PMTCT, Prevention of mother- to- child 
transmission.
Figure 5 Potential population net health effects from research. DALYs, disability- adjusted life- years; MDR, Multidrug resistant; 
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Figure 5 depicts the maximum net health gains that 
could be generated by research if it were to resolve the 
uncertainties around whether to include each of the 
21 interventions considered for the package. These 
estimates of the value of research follow interventions’ 
ordering by expected pNHE to visually help identify: 
(1) the expected ‘best buys’ for which there is substan-
tial value in reducing uncertainty around whether these 
interventions should be included within the HBP and (2) 
interventions for which there is potential value in further 
researching whether excluding them from the HBP is, 
indeed, the appropriate decision.
Comparison of figures 4 and 5 shows that, although 
‘male circumcision’ is expected to be a ‘best buy’, 
implementing it could lead to potentially large net 
health losses. As a result, resolving uncertainty around 
the decision to invest in this intervention could poten-
tially avert up to 67 762 net DALYs. In contrast, there is 
unsurprisingly no value in undertaking research on ‘first 
line management of new cases of tuberculosis’ in either 
adults or children since, as shown in figure 4, expected 
pNHE values for interventions 17 and 18 only span 
across net health gains.
Among the other interventions for which the presence 
of decision uncertainty had been identified, figure 5 
shows that resolving uncertainty around the decision 
to invest in CMAM (int 36)—currently expected to be 
cost- effective—and the decision to exclude ‘isoniazid 
preventive therapy for HIV +individuals no TB’ (int 31)—
currently expected to be cost- ineffective—could help 
avert up to 36 438 and 20 132 net DALYs, respectively. 
In summary, by applying the framework to the evidence 
presented in existing cost- effectiveness studies, we have 
identified that out of 21 interventions considered for the 
package, eight decisions about whether to an include an 
intervention within the HBP were uncertain and three 
(int 33, 36 and 31) showed potential for research to 
generate large health gains.
Exploratory analysis results including the 46 interven-
tions for which sensitivity analysis data was not available 
is provided in the online supplemental appendices. This 
indicates that several interventions for which no sensi-
tivity analysis results were presented may well repre-
sent priority areas for further research. In particular, 
research on the cost- effectiveness of two maternal inter-
ventions: management of obstructed labour (int 34) 
and caesarean section (int.10) could deliver substantial 
health gains (above 200 000 DALYs, respectively). This 
finding is, however, conditional on the assumption that 
the uncertainty around the incremental health benefits 
and incremental costs of these two interventions is of 
similar magnitude to the one found on average among 
the subset of 21 interventions for which sensitivity anal-
ysis data was available. This present exploratory analysis 
should therefore be complemented with expert opin-
ions and/or a deeper search of the evidence base but 
it usefully outlines those interventions such efforts may 
need to focus on.
What are the implications of a changing evidence base and 
uncertain measures of health opportunity cost?
Costs of treatment and baseline life expectancy are 
key drivers of cost- effectiveness that deserve particular 
attention as they are subject to change over time and 
may therefore require refining. For instance, the cost- 
effectiveness study15 that informs ‘paediatric ART’ (int. 
42) assumes a yearly per- patient treatment cost of $1436 
whereas recently reported prices of ART treatment in 
Malawi were around $100 per person.16 By combining 
information from both studies, the lifetime per- patient 
incremental cost of providing paediatric ART would 
drop from US$11 660 to US$1115. While our best guess 
of pNHE would remain negative, the decision to exclude 
paediatric ART from the package would no longer be so 
clear- cut as expectations of pNHE would now range from 
−544 761 to 140 400 net DALYs averted. In this context, 
undertaking research could help avert up to 13 000 net 
DALYs. In addition, in several studies of paediatric inter-
ventions, incremental health benefits were computed 
assuming a life expectancy at birth that is at least 10 years 
lower than the current estimate of 66.8 years for Malawi. 
For these interventions where costs are incurred in early 
years, but benefits can be reaped throughout a lifetime, 
a considerable lengthening of life expectancy will impact 
the magnitude of incremental health benefits, the extent 
of which will, however, depend on the discount rate 
applied.
The range of pNHE expected to be generated by 
each intervention intrinsically depends on the measure 
of health opportunity cost. This can be interpreted as 
how much a country can afford for averting a DALY and 
should ideally reflect the marginal productivity of the 
healthcare system17 but the latter is expected to be uncer-
tain. Since the larger the opportunity cost estimate, the 
more the HBP would expand, its validity could be prag-
matically gauged based on the proportion of a country’s 
healthcare budget that would be devolved to the HBP. 
While our current estimate of US$61/averted DALY may 
seem low,18 increasing it did not seem appropriate since 
at that value, the total HBP cost was already greater than 
the resources budgeted for it.3
CONCLUSIONS
We propose a framework to concurrently support HBP 
design and research prioritisation by quantifying the 
improvement in population net health benefits to be 
generated by a better- evidenced HBP. To overcome the 
technical and data- related barriers to the implementa-
tion of our framework, based on VOI methods, we have 
developed a stand- alone easy- to- use quantitative tool that 
provides estimates of the maximum potential population 
health benefits of research using only sensitivity analysis 
results reported in cost- effectiveness studies. Using this 
tool, application of the framework to Malawi’s HSSP 
helped identify three interventions for which there was 
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them in the HBP would generate positive or negative 
pNHEs. Across these interventions—male circumcision, 
CMAM and isoniazid prevention therapy in people living 
with HIV—research offers the potential to avert an esti-
mated 122 000 DALYs.
By facilitating the production of quantitative estimates 
of the health benefits of research, we hope this work can 
provide an important input into prioritising the alloca-
tion of research funds. This in turn can help to ensure 
that restricted healthcare resources are put to their best 
use and achieve greater health gains in populations 
of LMICs. This type of quantitative information also 
provides a basis for communication between countries 
and international research funders about interventions 
where further research is potentially valuable. In previous 
work we have shown how specific research proposals that 
address key uncertainties relating to the costs and effects 
of these interventions can be evaluated.19
Our VOI- HBP tool is hoped to enable a wide appli-
cation of the framework so that analysts within and 
supporting health ministries can: (1) identify the inter-
ventions which should be prioritised for funding based 
on current available evidence and (2) establish research 
priorities to address evidential requirements pertaining 
to cost- effectiveness, using simply secondary cost- 
effectiveness data at hand and without undertaking any 
additional statistical analysis. While the tool circumvents 
the high data and statistical burden that would normally 
be required to implement the framework, its computa-
tions inevitably rely on a set of structural assumptions 
regarding statistical distributions and underpinning 
parameters, in particular when data on correlation and 
minimum and maximum values of incremental benefits 
are not available. These assumptions can, however, be 
easily modified or removed to test for results’ sensitivity 
to them. In the present application of the framework to 
the evidence base used for designing Malawi’s HBP, addi-
tional analysis provided in online supplemental appen-
dices suggests the list of interventions with the largest 
potential for generating health gains from research was 
not sensitive to the assumptions used.
Analytical results generated by the application of the 
framework are, however, intended to support rather 
than prescribe decisions. They should be carefully 
appraised in light of: (1) the quality and relevance of 
the cost- effectiveness evidence base, including whether 
key drivers of cost- effectiveness findings need refining 
or updating and (2) results’ sensitivity to the choice of 
decision- analytic parameters such as the estimate of the 
health opportunity cost of spending healthcare funds.
In addition, the framework proposed focuses on health 
maximisation whereas stakeholders may consider wider 
social objectives when appraising the value of research 
studies. In the development of Malawi’s HSSP 2017–
2222, an extensive consultation underlined the need to 
consider health effects alongside four additional objec-
tives: reducing health inequalities and promoting finan-
cial protection, exceptional donor funded interventions, 
continuation of care and complementarities between 
interventions. Nevertheless, by quantifying how much 
population health research could generate by improving 
HBP design, our framework can provide a valuable input 
to deliberative research prioritisation processes that 
consider a wider range of social objectives. In Malawi, a 
National Health Research Taskforce, coordinated by the 
Department of Planning of the Ministry of Health, has 
been established to define research priorities to inform 
delivery of its next HSSP 2022–2027, to which the revised 
HBP will be central.13 The Taskforce is to play a key role in 
guiding the allocation of research funds coming from the 
government and from several overseas donor- channels. 
It is anticipated that our framework will provide valuable 
quantitative insight to help shape the new HSSP and 
support the Taskforce in setting out research priorities.
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